Freedom Capital Markets maintains Buy rating on Omada Health, $35 price target

Freedom Capital Markets reiterated a Buy rating and $35 price target for Omada Health, implying a 91.3% upside. The firm cites strong demand for Omada's integrated care solutions and resilience against competitors.

Original reporting
Published Oct 14, 2026, 7:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 7:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Freedom Capital Markets maintains Buy rating on Omada Health, $35 price target — source image
Decision brief

The 30-second read

Low
01

Why it matters

The rating update provides a modest bullish cue but lacks new material events; traders may watch for subsequent earnings or partnership news.

02

Market read

Analyst rating change offers limited trading impetus; relevance is low to moderate for investors in health‑tech equities.

03

What to watch

Potential competitive pressure from larger tech‑health players not reflected in the rating.

Relevance 5/10Novelty 4/10Timing: post-market today

Background

Freedom Capital Markets reiterated a Buy rating on Omada Health with a $35 price target, citing demand for integrated care and competitive positioning.

Market effects

Analyst rating may modestly influence health‑tech sector sentiment.

Limited to U.S. investors tracking digital health stocks.

Minimal global impact.

Counterpoint

Rating maintenance may be seen as a neutral signal; price target could be overly optimistic.

Key entities

  • Freedom Capital Markets

    Research firm issuing the rating.

  • Omada Health

    Digital health firm targeted by the rating.

Related articles

$OMDALowAI 8/10

Omada Health reports weight loss study results for GLP-1 program

Omada Health (NASDAQ:OMDA) presented a 12-week study at the World Obesity and Weight Management Congress, showing its GLP-1 Care Track program led to 6.0% average weight loss vs. 3.3% for usual care. The study, published in Diabetes, Obesity and Metabolism, involved 245 adults with obesity. Omada's program also improved body composition, well-being, and reduced depression/anxiety symptoms.

$OMDAHighAI 9/10

Omada Health (OMDA) Q2 2026 Earnings Call Transcript

Omada Health (OMDA) reported Q2 2026 revenue of $88 million, up 43% year over year, with GAAP gross margin of 73% and GAAP net income of $5 million. Adjusted EBITDA was $11 million. The company raised full-year revenue guidance to $334 million to $340 million and adjusted EBITDA to $21 million to $27 million, citing member growth and lower cost to serve.

$OMDAHigh

Omada Health Reports Second Quarter 2026 Results and Announces CEO Transition

Omada Health, Inc. (OMDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Omada Health Reports Second Quarter 2026 Results and Announces CEO Transition • Revenue Grew 43% and Total Members Increased 45% Year over Year, with Gross Margin Reaching a New Quarterly Record • Company Announces Sean Duffy to Become Executive Chair and Wei-Li Shao to Become Ch